The FDA breakthrough therapy program is designed to expedite approval of medical treatments for serious or life-threatening conditions in cases where preliminary tests have suggested significant improvement compared to existing treatments. Upon review, drugs approved as breakthrough therapies generally have less evidence to support them versus FDA approved non-breakthrough drugs and some do not require post-marketing studies.
Read more about this potential patient safety and quality issue here.